Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.26076 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA Network Open, 2024. Verfasst von Vikas Ostwal und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. Hauptthemen laut MEDLINE: Olanzapine, Antiemetics, Vomiting, Nausea. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Importance The role of olanzapine has not been adequately evaluated in moderately emetogenic chemotherapy (MEC) regimens with or without neurokinin-1 receptor antagonists.
Objective
To evaluate whether addition of olanzapine to an MEC regimen reduces nausea, vomiting, and use of nausea rescue medications among patients with solid malignant tumors. Design, Setting, and Participants This multicenter, open-label phase 3 randomized clinical trial included patients aged 18 years or older with solid malignant tumors who were receiving oxaliplatin-, carboplatin-, or irinotecan-based chemotherapy. The trial was conducted at 3 institutes in India from March 26, 2019, to August 26, 2023; the final cutoff date for analysis was September 10, 2023. Exposure Patients were randomized 1:1 to dexamethasone, aprepitant, and palonosetron with olanzapine (experimental group) or without olanzapine (observation group). The experimental group received 10 mg of olanzapine orally once at night on days 1 through 3 of the chemotherapy regimen. Main Outcomes and Measures The primary end point was complete response (CR), defined as the proportion of patients with no vomiting, no significant nausea (scored as <5 on a visual analog scale of 1 to 100), and no use of rescue medications for nausea. Secondary end points included the proportion of patients experiencing nausea and chemotherapy-induced nausea and vomiting (CINV), receiving rescue medications, and experiencing adverse events.
Results
A total of 560 patients (259 [64%] male; median age, 51 years [range, 19-80 years]) were randomized. The analysis included 544 patients with evaluable data (274 assigned to olanzapine and 270 to observation). Baseline characteristics were evenly matched between the 2 groups. The proportion of patients with CR was significantly greater in the group with (248 [91%]) than without (222 [82%]) olanzapine in the overall 120-hour treatment period ( P = .005). Likewise, there were significant differences between the olanzapine and observation groups for nausea control (264 [96%] vs 234 [87%]; P < .001) and CINV (262 [96%] vs 245 [91%]; P = .02) during the overall assessment period, and the proportion of patients receiving rescue medications significantly increased in the observation group (30 [11%]) compared with the olanzapine group (11 [4%]) ( P = .001). Grade 1 somnolence was reported by 27 patients (10%) following administration of chemotherapy and olanzapine and by no patients in the observation group. Conclusions and Relevance In this randomized clinical trial, the addition of olanzapine significantly improved CR rates as well as nausea and vomiting prevention rates in chemotherapy-naive patients who were receiving MEC regimens containing oxaliplatin, carboplatin, or irinotecan. These findings suggest that use of olanzapine should be considered as one of the standards of care in these chemotherapy regimens. Trial Registration Clinical Trials Registry–India (CTRI) Identifier: CTRI/2018/12/016643
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
- Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, Varanasi, India.
- Medical Oncology, AIG Hospitals, Gachibowli, Hyderabad, India.
- Department of Statistics, Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute, Mumbai, India.
- Department of Medical Oncology, PD Hinduja Hospital and Research Centre, Mumbai, India.
- School of Psychology I Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.
Zitieren
APA
Ostwal, V., Ramaswamy, A., Mandavkar, S., Bhargava, P., Naughane, D., Sunn, S. F., Srinivas, S., Kapoor, A., Mishra, B. K., Gupta, A., Sansar, B., Pal, V., Pandey, A., Bonda, A., Siripurapu, I., Muddu, V. K., Kannan, S., Chaugule, D., Patil, R., …, & Olver, I. (2024). Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.26076
Vancouver
Ostwal V, Ramaswamy A, Mandavkar S, Bhargava P, Naughane D, Sunn SF, et al. Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.26076
BibTeX
@article{Ostwal2024,
author = {Ostwal, Vikas and Ramaswamy, Anant and Mandavkar, Sarika and Bhargava, Prabhat and Naughane, Deepali and Sunn, Sharon Flavia and Srinivas, Sujay and Kapoor, Akhil and Mishra, Bal Krishna and Gupta, Anuj and Sansar, Bipinesh and Pal, Vikash and Pandey, Aparajita and Bonda, Avinash and Siripurapu, Indraja and Muddu, Vamshi Krishna and Kannan, Sadhana and Chaugule, Deepali and Patil, Rajshree and Parulekar, Manali and Dhanawat, Aditya and Trikha, Mehek and Ghosh, Jaya and Noronha, Vanita and Menon, Nandini and Patil, Vijay and Prabhash, Kumar and Olver, Ian},
title = {Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.26076}
}
EUVIMED